Therapeutic compounds and compositions
Inventors
Chrusciel, Robert A. • Gadwood, Robert C. • Hayward, Neil J. • Melnick, Michael J. • Navia, Manuel A. • Poel, Toni J. • Stassen, Frans L. • Stewart, Catherine A.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12084414-B2
Publication Date
2024-09-10
Expiration Date
Abstract
The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.
Core Innovation
The invention relates to a method of treating a subject in need thereof by maintaining an extracorporeal blood circuit. The method comprises contacting the blood of the subject with a compound of Formula (II) or a pharmaceutically acceptable salt thereof together with an additional anticoagulant agent. Formula (II) is defined by extensive structural substituent options and ring-forming conditions, with pharmaceutically acceptable salts and specific compound embodiments also disclosed.
The disclosure further describes pharmaceutical compositions and maintains an extracorporeal blood circuit in the extracorporeal setting. The disclosed compounds are presented as part of a treatment scheme that inhibits blood coagulation. The broader disclosure also identifies compound series associated with Factor XIa or kallikrein inhibition.
Related therapeutic contexts include treating or preventing thromboembolic disorders, reducing stroke risk, systemic embolism, deep vein thrombosis, pulmonary embolism, and angiodema, including hereditary angioedema. Representative chemical structures and stereochemical variants are included within the broader structural definitions.
Claims Coverage
The consolidated claim coverage contains one independent claim. It covers a method of treating a subject in need thereof to maintain an extracorporeal blood circuit by contacting the blood of the subject with a compound of Formula (II) or a pharmaceutically acceptable salt thereof together with an additional anticoagulant agent. Dependent claims and related disclosure refine the structural definition, anticoagulant selection, subject scope, functional effect, and specific depicted compound embodiments.
Extracorporeal blood circuit maintenance by Formula (II) compound and anticoagulant co-agent
A method of treating a subject in need thereof to maintain an extracorporeal blood circuit by contacting the blood of the subject with a compound of Formula (II) or a pharmaceutically acceptable salt thereof and an additional anticoagulant agent.
Formula (II) substituent-defined chemical entities
The compound of Formula (II) is defined by extensive substituent variables and ring-forming conditions, with broad options including heteroaryl, cycloalkyl, aryl, heterocyclyl, and functional group substitutions.
Specific anticoagulant and functional refinements
Dependent claims refine the additional anticoagulant agent, limit the subject to a mammal, and recite inhibition of blood coagulation.
Specific depicted compound embodiments
Dependent claims and related disclosure narrow the Formula (II) compound to specific depicted chemical structures and stereochemical variants.
Factor XIa or kallikrein inhibition
The disclosure identifies compounds associated with Factor XIa or kallikrein inhibition in connection with prevention or treatment of thromboembolic disorders and angiodema.
The claim coverage centers on maintaining an extracorporeal blood circuit using a Formula (II) compound or pharmaceutically acceptable salt together with an additional anticoagulant agent. The remaining claim refinements narrow the structural scope, anticoagulant selection, subject category, functional effect, and specific compound embodiments.
Stated Advantages
Maintains an extracorporeal blood circuit.
Inhibits blood coagulation.
Reduces stroke risk and systemic embolism, including non-central nervous system systemic embolism.
Treats or prevents thromboembolic disorders including deep vein thrombosis and pulmonary embolism.
Prevents or treats angiodema, including hereditary angioedema.
Factor XIa inhibition is associated with the therapeutic goals.
Documented Applications
Treating a subject in need thereof by maintaining an extracorporeal blood circuit through contacting the subject's blood with a Formula (II) compound or pharmaceutically acceptable salt together with an additional anticoagulant agent.
Treating or preventing thromboembolic disorders including deep vein thrombosis, pulmonary embolism, and systemic embolism.
Reducing stroke risk.
Preventing or treating angiodema, including hereditary angioedema.
Interested in licensing this patent?